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Background: Adverse drug reactions (ADRs) are recognised as a common cause of hospital admissions, and they
constitute a significant economic burden for hospitals. Hospital-based ADR monitoring and reporting programmes
aim to identify and quantify the risks associated with the use of drugs provided in a hospital setting. This
information may be useful for identifying and minimising preventable ADRs and may enhance the ability of
prescribers to manage ADRs more effectively. The main objectives of this study were to evaluate ADRs that
occurred during inpatient stays at the Hospital Geral de Palmas (HGP) in Tocantins, Brazil, and to facilitate the
development of a pharmacovigilance service.
Methods: A prospective study was conducted at HGP over a period of 8 months, from January 2009 to August
2009. This observational, cross-sectional, descriptive study was based on an analysis of medical records. Several
parameters were utilised in the data evaluation, including patient demographics, drug and reaction characteristics,
and reaction outcomes. The reaction severity and predisposing factors were also assessed.
Results: The overall incidence of ADRs in the patient population was 3.1%, and gender was not found to be a risk
factor. The highest ADR rate (75.8%) was found in the adult age group 15 to 50 years, and the lowest ADR rate was
found in children aged 3 to 13 years (7.4%). Because of the high frequency of ADRs in orthopaedic (25%), general
medicine (22%), and oncology (16%) patients, improved control of the drugs used in these specialties is required.
Additionally, the nurse team (52.7%) registered the most ADRs in medical records, most likely due to the job
responsibilities of nurses. As expected, the most noticeable ADRs occurred in skin tissues, with such ADRs are more
obvious to medical staff, with rashes being the most common reactions. Metamizole, tramadol, and vancomycin
were responsible for 21, 11.6, and 8.4% of ADRs, respectively. The majority of ADRs had moderate severity (58.9%),
thus requiring intervention. Type A reactions were the most common (82.1%). At least one predisposing factor was
present in 79.9% of the reports examined, and the most common predisposing factor was polypharmacy.
Conclusions: The results obtained will contribute to the development of strategies for the pharmacovigilance
service at HGP and other hospitals throughout the country, which will improve the quality of ADR reporting and
ensure safer drug use in Brazilian hospitals.* Correspondence: mcspranc@uft.edu.br
2Curso de Medicina, Universidade Federal do Tocantins, Av. NS 15 s/n (109
Norte), Palmas 77001-090, Brasil
Full list of author information is available at the end of the article
© 2013 Lobo et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lobo et al. BMC Pharmacology and Toxicology 2013, 14:5 Page 2 of 7
http://www.biomedcentral.com/bmcpharmacoltoxicol/2050-6511/14/1/5Background
An adverse drug reaction (ADR) is defined by the World
Health Organization (WHO) as any noxious, unintended,
or undesired effect of a drug that occurs at doses used in
humans for prophylaxis, diagnosis, or therapy [1]. ADRs
are a major cause of morbidity and place a substantial
burden on limited healthcare resources [2]. Multiple fac-
tors influence ADR susceptibility, including multiple drug
therapy, disease severity, age, and the type and number of
drugs prescribed [3-8]. Several studies have shown that
the proportion of patients admitted with ADRs ranges
from approximately 2.0 to 21.4%, whereas between 1.7
and 25.1% of inpatients are reported to have developed an
ADR during their hospital stay [9-12]. There are marked
differences in disease prevalence, access to medicines,
drug use patterns, and drug management systems bet-
ween developed and developing countries, and such dif-
ferences impact the frequency and nature of ADRs [13].
Reports of ADRs have become an important compo-
nent of monitoring and evaluation activities performed in
hospitals [14]. This information may be useful for identi-
fying and minimising preventable ADRs while generally
enhancing the ability of prescribers to manage ADRs
more effectively [15,16].
Few reports are available regarding the incidence of
ADRs in Brazilian hospitals. The Hospital Geral de Palmas
(HGP) is a highly complex, 220-bed, tertiary care refer-
ence centre and teaching hospital located in the city of
Palmas in Northern Brazil. An ADR reporting program
has existed in HGP since July 2001 and is coordinated by
the Hospital’s Department of Pharmacy Practice. The
ADR reporting unit of HGP is one of the reference centres
of the National Pharmacovigilance Program.
The present study was undertaken to (1) determine the
frequency of ADRs that occur in hospitalised patients and
to classify the reactions according to the demographics of
the affected patients and the preventability of the ADRs;
(2) describe the types of drugs involved; (3) report the
most common clinical manifestations associated with
these ADRs and their severity; and (4) assess the predic-
tive factors of ADRs.
Methods
Study design
A prospective study was conducted over a period of
8 months from January 2009 to August 2009 at HGP in
Tocantins, Brazil. HGP is a 220-bed tertiary care hospital
utilised by the entire state and its surrounding areas. The
hospital’s specialties are general medicine and surgery.
The study was observational, non-interventional, and
based on the ADRs reported by multiple departments of
HGP; the reports were coordinated by clinical pharma-
cists. Male and female inpatients, except those in the
Intensive Care Unit and Emergency Room, were includedin the study. HGP participates in standard pharmacovigi-
lance and employs a system of spontaneous reporting,
which was the form of reporting used in this study.
Functioning of the ADR reporting system at HGP
There was no organised pharmacovigilance program at
the hospital prior to the study. Clinical meetings with al-
lied hospital healthcare professionals raised awareness of
ADR monitoring and its importance. Attendees were
encouraged to report all suspected ADRs using various
reporting modalities, such as using a printed ADR notifi-
cation form (available at all nursing stations), reporting
ADRs by telephone, or directly reporting ADRs to an
attending clinical pharmacist in certain hospital depart-
ments. Nurses also completed notification forms. Many
forms were designed for this study, including a notifica-
tion form and a form to describe the ADR in detail. Notifi-
cation forms were kept in the participating wards. All
patients were assessed for ADRs during the study period.
In suspected cases, patients’ past medical history and
medication history were collected. To provide comple-
mentary information concerning adverse reactions, espe-
cially unexpected reactions, ADRs were spontaneously
reported as part of standard care. Patients were monitored
daily throughout their hospital stay, and some their med-
ical records were reviewed daily and others after dis-
charge. The suspected ADRs were carefully analysed and
documented. All relevant data, including all drugs that
patients received prior to the reaction onsets and their
respective dosages, the most frequent routes of adminis-
tration, the dates of the reaction onsets, and the patients’
allergy status (to drugs and foods), were noted. Thus, the
ADRs confirmed by the physicians and research pharma-
cists were classified and subjected to a severity assess-
ment. Furthermore, information regarding the ADRs
reported in the unit was published six times a year in a
news bulletin of the Department of Pharmacovigilance
(PHS) and was disseminated to all health care profes-
sionals at the hospital.
After initial notification of a suspected ADR, additional
details were collected concerning previous allergies, con-
comitant medications, comorbidities, ADR management
and outcome, and other details necessary for evaluation.
These data were collected by reviewing patients’ records
and noting the reporters’ comments. The collected data
were recorded in separate ADR documents for further
assessment. The physician responsible for the case was




The patients’ age and gender were considered in the
evaluation. In accordance with a previous paper, patients
Lobo et al. BMC Pharmacology and Toxicology 2013, 14:5 Page 3 of 7
http://www.biomedcentral.com/bmcpharmacoltoxicol/2050-6511/14/1/5were divided into three age groups: children and teen-
agers (0–18 years old), adults (19–59 years old), and the
elderly (over 60 years old).Reaction characteristics
The ADRs were classified according to the Rawlins and
Thompson classification system as type A or type B [17].
The severity of the reaction was determined according to
the classification system of Hartwig et al. [18-20]. Mild
reactions were those that were self-limiting, resolved over
time without treatment, and did not extend a patient’s
hospital stay. Moderate ADRs were defined as those that
required therapeutic intervention and prolongation of the
hospital stay by one day but that resolved within 24 hours
due to a change in drug therapy or the administration of a
specific treatment to prevent further adverse outcomes.
Severe ADRs threatened patients’ lives, caused disability,
led to hospitalisation, prolonged hospital stays, required
intensive medical care, or led to death. Reactions were fur-
ther classified depending on the organ system affected.Drug characteristics
The drugs involved in the ADRs were categorised into
various drug classes according to the anatomical thera-
peutic chemical (ATC) classification, based on the 2005
WHO-ATC Index [21].Management and outcomes
Patients’ outcomes were reported as death, fully recov-
ered (during hospitalisation), recovering (but not fully
recovered during hospitalisation), or unknown (not docu-
mented after the initial report in the chart). The manage-
ment strategies used for the ADRs were categorised as
drug withdrawal, dose reduction, additional treatment for
the ADR, or no change in regimen with no additional
treatment.Predisposing factors
Factors with the potential to predispose patients to ADRs
in the individual reports were evaluated. Predisposing
factors were generally classified according to age, gender,
multiple and intercurrent disease states, and polyphar-
macy [3-8]. Ages above 60 (geriatrics) and below 18
(paediatrics) were regarded as a predisposing factor under
the age criterion. Polypharmacy was considered to be minor
(2–3 drugs), moderate (4–5 drugs), or major (>5 drugs)
based on the characterisation by Wong [6]. Gender was
considered a factor only if there was previous informa-
tion indicating that the patient’s gender predisposed the
patient to the reaction in question.Statistical analysis
Student’s t-test was used to compare means, and the χ2
test was used for the other variables. A two-tailed P value
of less than 0.05 was considered statistically significant.Ethics and consent
The study was approved by the Institutional Human
Ethics Committee of Centro Universitário Luterano de
Palmas-Tocantins, filed under number 794/2008, and
was conducted in accordance with the ethical guidelines
of the Declaration of Helsinki (created in 1964 and
revised in 2002). Permission to conduct the study was
obtained from the Medical Superintendent of the Hos-
pital Geral de Palmas.
Results
Throughout the 8-month study period, 95 ADRs were
confirmed and reported in 81 inpatients. There were
2995 patient admissions at locations other than HGP,
and the overall incidence of ADRs during hospitalisation
in this patient group was 3.1%.
ADRs were more frequent in males (55.7%) than in
females (44.3%). No significant difference was observed in
the ADRs between males and females during the hospital
stay (χ2c = 1.05, P = 0.26). The rates of ADRs in paediatric
(<18 years), geriatric (>60 years), and adult patients were
18.9, 20.0, and 61.0%, respectively. The rates of ADRs in
adult patients were significantly higher than those in
paediatric and geriatric patients (χ2 = 33; P = 0.0001).
Details regarding the classification and assessment of
ADRs are provided in Table 1.
Certain factors contributed to the occurrence of ADRs,
such as the number of different drugs administered con-
comitantly. To assess contributing factors, we calculated
the median number of prescriptions per patient that
were suspected of causing ADRs, which was 6.8 medica-
tions/prescription. We also found that the risk of ADRs
was higher in 7.4% of the patients who were using more
than 6 medications.
The severity assessment of the ADRs showed that over
half of the reactions reported were moderate (58.9%) (χ2 =
29.3, P = 0.00001), followed by mild (25.3%) and severe
(15.8%) reactions. There were no fatal reactions. Complete
recovery was achieved in 26.3% of patients with ADRs,
5.8% were in the recovery process, and 57.9% were classi-
fied as having ‘unknown outcomes’ (i.e., outcomes that
could not be assessed due to a lack of recorded reports).
Treatment with the offending drug was interrupted in
50.5% of patients. Another drug was substituted for the
offending drug in 27.4% of patients, and other drugs were
added to relieve the symptoms in 57.0% of patients; the
drug dosage was not reduced in any patient to ameliorate
symptoms. Treatment was unchanged in 37.8% of patients
Table 1 Patient characteristics
Age group Number (%) of ADR reports Gender group Number (%) of ADR reports
(n = 95) (n = 95)
Paediatric (0–18 years) 18 (19.0) Male 53 (55.7)
Adult (19–59 years) 58 (61.0) Female 42 (44.3)
Geriatric (>60 years) 19 (20.0)
Total 95 (100.0) 95 (100.0)
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reactions (82.1%).
The most common drugs causing ADRs and their reac-
tion details are shown in Table 3. Analgesics (e.g., meta-
mizole) were associated with approximately one-third of
all ADRs reported (21.0%). Tramadol produced the high-
est number of reactions (11.6%), followed by vancomycin
(8.4%), phenytoin (6.3%), and ceftriaxone (4.1%). Itching
was the most common ADR reported (26.3%), followed
by rashes and oedema (13.7%). The organ systems
affected by the ADRs are shown in Table 4. The skin was
found to be the most commonly affected organ system
(34.5%), followed by the metabolic (16.5%) and gastro-
intestinal (14.2%) systems.
The minimum amount of time prior to ADR develop-
ment was 1 day of hospitalisation, the median time was
6 days, and the maximum time was 180 days. The reac-
tions that manifested during a period of 11 to 30 days of
hospitalisation constituted 31.6% of the total number of
reactions identified in this study, equivalent to the ave-
rage percentage of reactions that occurred among
inpatients in the Orthopaedics and General Medicine
Departments.Table 2 Management, outcomes, and severity of ADRs











Stopped the medication 48 (50.5)
Reduced the dose 0
Added another drug to relieve the
symptoms
54 (57.0 )
Substituted another drug 26 (27.4)
No change 36 (37.8 )The highest ADR rate in young adults occurred in
the Orthopaedics Department (25%). ADRs occurred
in the General Medicine (22%) and Oncology (16%)
Departments at the second and third greatest frequen-
cies, respectively.
Discussion and conclusion
A total of 30-91% of ADRs could be avoided, thus saving
health system resources and reducing harm to patients
[22]. To work together toward ADR prevention, physi-
cians, nurses, and pharmacists should be aware of poten-
tial clinical problems by assessing medicines that a patient
has used recently; allergies or unusual reactions to any
medicine, food, or product; special dietary or eating
restrictions; and whether the patient is pregnant, breast-
feeding, or planning pregnancy in the near future [23].
New drugs should also be closely monitored to avoid un-
known and severe ADRs [24].
The fundamental role of pharmacovigilance centres is
to collect and process data regarding ADRs and to sup-
port hospitals in the identification of these reactions
[25]. The centres’ actions serve to reduce risks related to
medication usage, improve patients’ quality of life, pre-
vent iatrogenic diseases, and minimise health expenses.
The frequency of ADRs found in this study, which was
based on inpatient records, was 3.1%. This value could
have been greater if HGP had adopted intensive monitor-
ing techniques or computer programs to supervise ADRs.
The main reason for this low number is that our data were
derived from spontaneous reporting. The ADR rate was
low compared with the results of a meta-analysis con-
ducted by Lazarou et al. [12], who reported that 15.1% of
hospitalised patients develop an ADR. Other factors that
may have contributed to this low number include the
non-reporting of mild ADRs and the lack of guidelines
and procedures for identification, registration, and notifi-
cation. Reluctance to register ADRs persists, especially
among nurses, as the registering of ADRs could signal
medical mistakes or poor quality of care. This reluctance
results in fewer ADR notifications and was also observed
in Sobravime’s study [13].
There is no agreement among studies regarding the in-
cidence of ADRs with respect to gender. Certain authors
[3,4] have reported that women are more susceptible to
ADRs, possibly due to their high medication use, obstetric
Table 3 Drug classes and individual drugs most commonly associated with ADRs
Drug class Drug (ATC) Total number (%)
(n = 95)
Antibiotics Cefalexin (J01DB01) 1 (1.0)
Cefalotin (J01DB03) 6 (6.3)
Cefazolin (J01DB04) 1 (1.0)
Cefepime (J01DE01) 3 (3.1)
Ceftriaxone (J01DD04) 4 (4.2)
Imipenem (J01DH51) 2 (2.1)
Oxacillin (J01CF04) 1 (1.0)
Rifampicin (J04AB02) 1 (1.0)
Vancomycin (J01XA01) 8 (8.4)
Analgesics Metamizole (N02BB02) 20 (21.0)
Paracetamol (N02BE01) 1 (1.0)
Antipsychotics Chlorpromazine (N05AA01) 1 (1.0)
Olanzapine (N05AH03) 1 (1.0)
Risperidone (N05AX08) 1 (1.0)
Opioids Fentanyl (N01AH02) 1 (1.0)
Tramadol (N02AX02) 11 (11.6)
Benzodiazepine Diazepam (N05BA01) 1 (1.0)
Midazolam (N05CD08) 1 (1.0)
ACE inhibitors Captopril (C09BA01) 1 (1.0)
Enalapril (C09AA02) 2 (2.1)
Antiarrhythmic Amiodarone (C01BD01) 2 (2.1)
Local anaesthetic Bupivacaine (N01BB01) 1 (1.0)
Anticonvulsant Phenytoin (N03AB02) 6 (6.3)
Beta-blocker Carvedilol (C07AG02) 1 (1.0)
Antiemetic Metoclopramide (A03FA01) 2 (2.1)
H2 receptor antagonist Ranitidine (A02BA02) 2 (2.1)
Antidiuretic Furosemide (C03CA01) 4 (4.2)
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levels. Other researchers [26-28] have found the incidence
of ADRs to be unrelated to gender, which supports our
finding that ADRs did not differ significantly between
men and women.Table 4 Organ systems affected by ADRs and the most
commonly reported reactions




Central nervous system 12 (9.0)
Cardiovascular 5 (3.7)




Respiratory 2 (1.5)Age is considered a risk factor for the occurrence of
ADRs [29]. Therefore, children and the elderly, due to
metabolic system alterations, require careful orientation
and follow-up to avoid ADR occurrences and complica-
tions. However, in our study, the incidence of ADRs in
adults (61.0%) was significantly higher than that in the
other age groups [26,30]. These results seem to contradict
those of Passarelli [4], who found that the elderly have a
higher risk of ADRs. These conflicting results may be due
to the dosage adjustments of paediatric and geriatric pre-
scriptions as well as the higher number of young adults
who are hospitalised at HGP.
The incidence of adverse reactions increases exponen-
tially, but not necessarily simultaneously, with the number
of drugs administered during a certain period [6]. Our
study demonstrated that the usage of 6 to 10 medications
per patient increased the risk of ADRs in 7.4% of cases.
Extension of hospital stay is also considered a risk factor
for ADRs [26]. The highest ADR frequency (approximately
50%) occurred during the first five days of hospitalisation.
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was 1 day of hospitalisation, the median time was 6 days,
and the maximum time was 180 days. The percentage of
reactions that manifested during a period of 11 to 30 days
of hospitalisation was 31.6%, which is equivalent to the
average percentage of reactions among inpatients of the
Orthopaedics and General Medicine Departments at HGP.
The higher ADR rate in young adults is related to the
higher ADR frequency in the Orthopaedics Department
(25%). These results revealed a correlation between the
elevated number of young adults hospitalised and the
number of traumas caused by motorcycle accidents, which
are the second most common cause of hospitalisation at
HGP. The second and third highest prevalence of ADRs
occurred in the General Medicine (22%) and Oncology
(16%) Departments, most likely due to the greater expos-
ure to medication in the General Medicine Department
and to the adverse effects of antineoplastic medications in
the Oncology Department.
It was observed that several organ systems were affected
by medications. However, in accordance with other studies
[4,31], the highest frequency (48.4%) of adverse reactions
occurred in the dermatological system, manifesting as for-
mication, skin rashes, flushing, and dried skin. Eleven
reactions were registered simply as allergic reactions with
no further description in the records regarding the asso-
ciated reaction manifestation, compromising the quality of
the records and the notification process.
In our study, analgesics caused the highest rate of ADRs,
followed by antibiotics. Our results are in accordance with
those of a study by Bates [32], possibly due to the elevated
consumption of such medications at HGP. Risperidone,
olanzapine, ceftriaxone, vancomycin, and furosemide were
responsible for severe ADRs (type B); although the medi-
cations’ dose dependence and pharmacological properties
were not indicated in the reports, severe ADR cases are
frequently immune- or genetically related and usually
prolong hospitalisation or require follow-up treatment.
However, the majority of the ADRs studied were type A
reactions (84.2%).
Due to intervention, the majority of ADRs were of
moderate severity, and there was a significant difference
in the degree of severity of the ADRs based on the re-
cords analysed.
A few doctors were able to control the ADRs by discon-
tinuing the offending medication (50%). In other cases,
clinical treatments were implemented using antihista-
mines, corticoids, antidotes, zinc dioxide, and vitamin
creams to relieve symptoms, whereas no treatment was
administered in some cases either due to the presence of
only a mild ADR or because the offending medication was
unknown (13%).
In conclusion, the ADRs that occurred at our hospital
are comparable to those reported by other studiesperformed in Brazilian and foreign hospitals; neverthe-
less, certain aspects were different. The number of pre-
scribed drugs and the length of drug use constitute risk
factors for ADRs; monitoring these factors requires a re-
view of clinical protocols, the quality of the prescription,
and the therapeutic arsenal. Among the prescribed med-
ications, metamizole, tramadol, and vancomycin caused
the most ADRs due to their frequent usage and the in-
herent characteristics of these drugs. It is evident that
pharmacovigilance systems are needed to facilitate ADR
follow-ups by health professionals directly involved in
patient care.
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